OpenSourceTB:Story so far: Difference between revisions
Matthew Todd (talk | contribs) (→General Background to TB: links to current portfolios) |
Matthew Todd (talk | contribs) (→General Background to TB: first refs) |
||
| Line 6: | Line 6: | ||
The [http://www.tballiance.org/ TB Alliance] and the [http://www.newtbdrugs.org/ Working Group on New TB Drugs] host pages detailing the current pipeline in discovery ([http://www.tballiance.org/portfolio/discovery-portfolio 1], [http://www.newtbdrugs.org/pipeline-discovery.php 2]) and development ([http://www.tballiance.org/portfolio 1], [http://www.newtbdrugs.org/pipeline.php 2]) phases. | The [http://www.tballiance.org/ TB Alliance] and the [http://www.newtbdrugs.org/ Working Group on New TB Drugs] host pages detailing the current pipeline in discovery ([http://www.tballiance.org/portfolio/discovery-portfolio 1], [http://www.newtbdrugs.org/pipeline-discovery.php 2]) and development ([http://www.tballiance.org/portfolio 1], [http://www.newtbdrugs.org/pipeline.php 2]) phases. | ||
Antimicrobial resistance is a major and growing problem.[http://www.who.int/mediacentre/factsheets/fs194/en/ WHO Report] There are calls for more global efforts to address the problem[http://www.nature.com/news/policy-an-intergovernmental-panel-on-antimicrobial-resistance-1.15275 Farrar Nature Article 2014, 10.1038/509555a] and exploration of research models [http://www.nature.com/news/a-three-step-plan-for-antibiotics-1.15291 "driven by public need rather than market forces", 10.1038/509533a] | |||
Tuberculosis is a major public health problem, with one-third of the world's population infected with the causative agent, Mycobacterium tuberculosis, resulting in 9 million cases of clinical TB and 1.3 million deaths.[http://www.who.int/tb/publications/global_report/en/ 2015 WHO TB report] | |||
The incidence of TB worldwide is worsened by the current HIV/AIDS pandemic because | |||
There are multi-drug resistant strains (MDR-TB) and now strains that are resistant to all known treatments. | |||
There is a pressing need for new small molecule drugs to treat this disease. | |||
The [http://www.who.int/tb/post2015_strategy/en/ End TB Strategy] was adopted by the World Health Assembly in May 2014. This aims to reduce TB deaths by 90% between 2015 and 2030, and reduce new cases by 80%. The [http://www.who.int/tb/publications/global_report/gtbr2015_executive_summary.pdf?ua=1 resolutions of the strategy] include #72 to "Develop new drugs and regimens for the treatment of all forms of tuberculosis" and #73 to "Enhance research to detect and treat latent infection...These strategies should include new medicines" | |||
Revision as of 16:05, 10 December 2015
Open Source TB was started in 2014 through a partnership between Matthew Todd at The University of Sydney and GlaxoSmithKline Tres Cantos, funded by the OpenLab Foundation. This initial project examined the first three OSTB Series. The initial grant, which finished in August 2015, created the online platform of this wiki, the Landing Page, the GitHub platform and the Twitter account. These are free to use by anyone, and people are encouraged to use the OSTB online presence to help run their own projects.
General Background to TB
The TB Alliance and the Working Group on New TB Drugs host pages detailing the current pipeline in discovery (1, 2) and development (1, 2) phases.
Antimicrobial resistance is a major and growing problem.WHO Report There are calls for more global efforts to address the problemFarrar Nature Article 2014, 10.1038/509555a and exploration of research models "driven by public need rather than market forces", 10.1038/509533a
Tuberculosis is a major public health problem, with one-third of the world's population infected with the causative agent, Mycobacterium tuberculosis, resulting in 9 million cases of clinical TB and 1.3 million deaths.2015 WHO TB report
The incidence of TB worldwide is worsened by the current HIV/AIDS pandemic because
There are multi-drug resistant strains (MDR-TB) and now strains that are resistant to all known treatments.
There is a pressing need for new small molecule drugs to treat this disease.
The End TB Strategy was adopted by the World Health Assembly in May 2014. This aims to reduce TB deaths by 90% between 2015 and 2030, and reduce new cases by 80%. The resolutions of the strategy include #72 to "Develop new drugs and regimens for the treatment of all forms of tuberculosis" and #73 to "Enhance research to detect and treat latent infection...These strategies should include new medicines"
